Gradalis
Carrollton, US · Founded 2014 · Delaware corporation · 2 known investors
Gradalis develops Vigil, a patient-specific immunotherapy studied in research and clinical trials for treating ovarian cancer, with potential use in other solid tumors. The therapy can be used on its own or alongside other cancer treatments.
Founders & leadership
Gradalis was founded in 2014 by John Nemunaitis and Shanahan.
JN
John NemunaitisCo-Founder & Chief Scientific Officer
S
ShanahanFounder and Chairman
DM
David M. ShanahanExecutive
ME
Mark EarlyExecutive
EB
Ernest BognarExecutive
GW
Gladice WallravenExecutive
RL
Renee LarsonExecutive
JN
John Nemunaitis, M.D.Named on SEC filing
Board
HR
Harry R. JacobsonBoard director
JC
Joe C. CunninghamBoard director
JF
RP
Robert P. LandinBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$56.7M disclosed across 2 rounds · 2018–2025
▶$12.7MraisedJun 2025 · 24 investors · BiotechnologyRule 506(b)
▶$12.7MraisedJun 2025 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John NemunaitisExecutive Officer, Director
- Harry R. JacobsonDirector
- Joe C. CunninghamDirector
- Joseph F. BerryDirector
- Robert P. LandinDirector
- David M. ShanahanExecutive Officer, Director
- Scott SeamanDirector
- Mark EarlyExecutive Officer
- Offering amount
- $30M
- Amount sold
- $12.7M
- Minimum investment
- $250K
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$43.9MraisedApr 2018 · 36 investors · PharmaceuticalsRule 506(b)
▶$43.9MraisedApr 2018 · 36 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ernest BognarExecutive Officer
- David ShanahanExecutive Officer, Director
- Gladice WallravenExecutive Officer
- Joe Cunningham, M.D.Director
- Harry Jacobson, M.D.Director
- Robert LandinDirector
- Thomas LylesDirector
- John Nemunaitis, M.D.Executive Officer, Director
- Renee LarsonExecutive Officer
- Scott SeamanDirector
- Offering amount
- $55M
- Amount sold
- $43.9M
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Genialis12 shared keywordsGenialis is a precision oncology company that applies data analysis to help drug developers understand mechanisms of action, resistance, and patient stratification for cancer therapies. It supports pharmaceutical partners in advancing molecules through clinical trials toward becoming effective medicines.
Alumis10 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Zentalis10 shared keywordsZentalis is a clinical-stage pharmaceutical company developing azenosertib, an investigational oral therapy that inhibits WEE1 kinase to disrupt the cell-cycle safeguards cancer cells use to survive. It focuses on providing physicians and patients with a targeted, non-chemotherapy oral treatment option in oncology.
Parabilis Medicines9 shared keywordsHelicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules. The platform uses AI and simulation to engineer helical peptides with non-canonical amino acids for precision binding across a range of therapeutic applications.
Prellisbio9 shared keywordsPrellis Biologics runs an antibody discovery platform that uses two-photon laser-bioprinted human immune organoids combined with machine learning to identify fully human antibody therapeutics. It develops a portfolio of antibody drug candidates across multiple disease areas and partners with biotech and pharmaceutical companies.
株式会社モダリス8 shared keywordsModalis Therapeutics develops therapeutics using CRISPR gene-editing technology and provides its platform technology for drug development. It operates in the biotechnology sector.
GRAIL7 shared keywordsGRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear. The test is offered by prescription in the United States and through partnerships with healthcare systems, insurance carriers, and diagnostic platforms.
Exelixis7 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies competing with Gradalis for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $650K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $199K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $124.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2006 | $124.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Gradalis do?
- Gradalis develops Vigil, a patient-specific immunotherapy studied in research and clinical trials for treating ovarian cancer, with potential use in other solid tumors. The therapy can be used on its own or alongside other cancer treatments.
- Who founded Gradalis?
- Gradalis was founded by John Nemunaitis, Shanahan in 2014.
- Who are Gradalis's investors?
- Gradalis's investors include WP Global Partners, WP Explorer.
- How much funding has Gradalis raised?
- Gradalis has disclosed $56.7M raised across 2 rounds.
- Where is Gradalis headquartered?
- Gradalis is headquartered in Carrollton, US.